News
BIOA
21.77
-0.59%
-0.13
Weekly Report: what happened at BIOA last week (0713-0717)?
Weekly Report · 6d ago
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Seeking Alpha · 07/19 19:10
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Barchart · 07/14 03:30
Weekly Report: what happened at BIOA last week (0706-0710)?
Weekly Report · 07/13 10:24
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure
Simply Wall St · 07/10 02:22
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
TipRanks · 07/09 10:06
Weekly Report: what happened at BIOA last week (0629-0703)?
Weekly Report · 07/06 10:28
Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102
Simply Wall St · 07/02 15:27
BioAge Labs principal accounting officer Shane Barton disposes of 62,566 common shares for $1,578,254.20
PUBT · 07/01 20:27
BioAge Labs (BIOA) Following QUELL CV Trial Start Is The Stock A Bargain
Simply Wall St · 06/29 21:16
Weekly Report: what happened at BIOA last week (0622-0626)?
Weekly Report · 06/29 10:23
BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically?
Simply Wall St · 06/25 12:21
BioAge Labs: Developing A 'Pipeline In A Pill'
Seeking Alpha · 06/24 21:11
Weekly Report: what happened at BIOA last week (0615-0619)?
Weekly Report · 06/22 10:33
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
TipRanks · 06/18 16:32
Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)
TipRanks · 06/17 13:30
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)
TipRanks · 06/17 11:00
BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102
PUBT · 06/16 12:16
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
TipRanks · 06/16 12:08
BIOAGE LABS ANNOUNCES FIRST PARTICIPANT DOSED IN QUELL-CV, A PHASE 2 PROOF-OF-CONCEPT TRIAL OF BGE-102, A NOVEL ORAL NLRP3 INHIBITOR, IN PATIENTS AT ELEVATED CARDIOVASCULAR RISK
Reuters · 06/16 12:00
More
Webull provides a variety of real-time BIOA stock news. You can receive the latest news about BioAge Labs Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.